Benzamides and related inhibitors of factor Xa
View Patent ↗Novel benzamide compounds including their pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives having activity against mammalian factor Xa are described. Compositions containing such compounds are also described. The compound and compositions are useful in vitro or in vivo for preventing or treating coagulation disorders.
1. A compound of the formula:
A-D-E-G-J-K
wherein:
A is a 5-10 membered saturated monocyclic heterocyclic ring system containing 1-4 heteroatoms selected from N, O and S, wherein 1-2 ring atoms of the heterocyclic ring system are substituted with 1-2 R 1 groups;
R 1 is C 1-6 -alkyl;
D is phenyl or pyridine where the phenyl is attached to rest of the compound in the 1,4-position and the pyridine is attached to the rest of the compound in the 2,5-position;
E is —C(═O)—NH— or —NH—C(═O)—;
G is a phenylene group wherein the ring carbon atoms of the phenylene group are substituted with 0-2 R 1d groups and the phenylene group is attached to the rest of the compound at the 1,2-position;
R 1d is —(CH 2 ) 0-6 OR 2d ;
R 2d is H or C 1-6 -alkyl;
J is —C(═O)—NH— or —NH—C(═O)—;
K is a phenyl substituted with 0-3 R 1e groups;
R 1e is a member independently selected from the group consisting of: halo and —(CH 2 ) 0-2 —O—R 2e ;
R 2e is independently a member selected from the group consisting of: H and —C 1-4 -alkyl;
or a pharmaceutically acceptable isomer, salt, hydrate, or prodrug derivative thereof.
2. The compound of claim 1 , wherein E is —N(H)—C(O)—.
3. The compound of claim 1 , wherein J is —N(H)—C(═O)—.
4. The compound of claim 1 , wherein R 1 is methyl.
5. The compound of claim 1 , wherein A-D- is
6. The compound of claim 1 , wherein E is —C(═O)—NH—.
7. The compound of claim 1 , wherein R 1d is —OR 2d .
8. The compound of claim 7 , wherein R 1d is —OH.
9. The compound of claim 1 , wherein J is —C(═O)—N(—R 6 )— and R 6 is hydrogen.
10. The compound of claim 1 , wherein R 1e is chloro.
11. The compound of claim 1 , wherein R 1e is —OCH 3 .
12. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a pharmaceutically effective amount of a compound of claim 1 .